【レポートの概要（一部）】
PART 01: Executive summary
• Highlights
PART 02: Scope of the report
• Market overview
• Top-vendor offerings
• Assumptions
PART 03: Market research methodology
• Research methodology
• Economic indicators
PART 04: Introduction
• Key market highlights
PART 05: Disease overview
• Understanding the disease
• Etiology
• Signs and symptoms
• Diagnosis
• Management
• Economic burden
• Epidemiology
PART 06: Pipeline portfolio
PART 07: Market landscape
• Market overview
• Market size and forecast
• Five forces analysis
PART 08: Market segmentation by type of disease
• RA
• MS
• PsA
• IBD
• AS
• SLE
• Global RA drugs market
• Clinical trials for RA
• Global MS drugs market
• Global PsA drugs market
• Global IBD drugs market
• Global AS drugs market
• Global SLE drugs market
PART 09: Market segmentation by mechanism of action
• TNF inhibitors
• IL-1 blockers
• COX inhibitors
• PDE4 inhibitors
• Others
PART 10: Market segmentation by drug class
• DMARDs
• NSAIDs
• Corticosteroids
• Analgesics
• Immunosuppressants
• Others
PART 11: Market segmentation by type of molecule
• Biologics
• Small molecules
PART 12: Market segmentation by ROA
• Oral
• Parenteral
• Topical
PART 13: Market segmentation by dosage form
• Solid
• Liquid
• Semi-solid
PART 14: Geographical segmentation
• Autoimmune diseases drugs market in the Americas
• Autoimmune diseases drugs market in US
• Autoimmune diseases drugs market in EMEA
• Autoimmune diseases drugs market in APAC
• Autoimmune diseases drugs market in Japan
• Autoimmune diseases drugs market in China
PART 15: Market drivers
• Rising prevalence of autoimmune diseases
• Growing older population
• Dominance of biologics
• Unmet medical needs
• Promising pipeline
PART 16: Impact of drivers
PART 17: Market challenges
• Increasing cost of biologics
• Loss of patent exclusivity of branded therapies
• Complex nature of autoimmune diseases
• Preference for CAMs
• Adverse effects
PART 18: Impact of drivers and challenges
PART 19: Market trends
• Emergence of biosimilars
• Patient assistance programs
• Increase in public awareness programs
• Strategic alliances
• Popularity of off-label and traditional treatment options
PART 20: Vendor landscape
• Competitive scenario
• Market analysis 2015
• AbbVie
• Johnson & Johnson
• Biogen
• Amgen
• Pfizer
• F. Hoffmann-La Roche
• Other prominent vendors
PART 21: Appendix
• List of abbreviations
PART 22: Explore Technavio
[List of Exhibits]
Exhibit 01: Product offerings
Exhibit 02: Etiology of autoimmune diseases
Exhibit 03: Signs and symptoms of autoimmune diseases
Exhibit 04: Diagnostic methods for autoimmune diseases
Exhibit 05: Non-pharmacological therapies used for autoimmune diseases
Exhibit 06: Pharmacotherapy therapies used for autoimmune diseases
Exhibit 07: Top drugs for autoimmune diseases
Exhibit 08: Average annual treatment costs of RA in US and Europe 2014 ($ billions)
Exhibit 09: Average annual treatment costs of MS across countries 2014 ($ billions)
Exhibit 10: Average annual treatment costs of PsA across countries 2014 ($ billions)
Exhibit 11: Prevalence and incidence of SLE
Exhibit 12: Pipeline molecules for RA
Exhibit 13: Pipeline molecules for MS
Exhibit 14: Pipeline molecules for PsA
Exhibit 15: Pipeline molecules for CD
Exhibit 16: Pipeline molecules for UC
Exhibit 17: Pipeline molecules for SLE
Exhibit 18: Global autoimmune diseases drugs market 2015-2020 ($ billions)
Exhibit 19: Five forces analysis
Exhibit 20: Global autoimmune diseases drugs market segmentation by type of disease
Exhibit 21: Global autoimmune diseases drugs market by type of disease 2015
Exhibit 22: Global autoimmune diseases drugs market: YoY revenue and growth based on autoimmune diseases 2015-2020
Exhibit 23: Global RA drugs market 2015-2020 ($ billions)
Exhibit 24: Global RA drugs market by drug class 2015
Exhibit 25: Top-vendor offerings for global RA drugs market
Exhibit 26: RA clinical trial by Phase 2015
Exhibit 27: RA clinical trial by status 2015
Exhibit 28: Drivers and challenges of global RA drugs market
Exhibit 29: Global MS drugs market 2015-2020 ($ billions)
Exhibit 30: Global MS drugs market by molecule type 2015
Exhibit 31: Top-vendor offerings for global MS drugs market
Exhibit 32: Drivers and challenges of global MS drugs market
Exhibit 33: Global PsA drugs market 2015-2020 ($ billions)
Exhibit 34: Global PsA drugs market segmentation by MOA 2015
Exhibit 35: Top-vendor offerings for global PsA drugs market
Exhibit 36: Drivers and challenges of global PsA drugs market
Exhibit 37: Global IBD drugs market 2015-2020 ($ billions)
Exhibit 38: Global IBD drugs market by type of disease 2015
Exhibit 39: Global IBD drugs market by drug class 2015
Exhibit 40: Top-vendor offerings for global IBD drugs market
Exhibit 41: Drivers and challenges of global IBD drugs market
Exhibit 42: Global AS drugs market 2015-2020 ($ billions)
Exhibit 43: Global AS drugs market by MOA 2015
Exhibit 44: Top-vendor offerings for global AS drugs market
Exhibit 45: Drivers and challenges of global AS drugs market
Exhibit 46: Global SLE drugs market 2015-2020 ($ billions)
Exhibit 47: Drivers and challenges of global SLE drugs market
Exhibit 48: Global autoimmune diseases drugs market segmentation by MOA
Exhibit 49: Average percentage of patients receiving TNF inhibitors 2010 and 2015
Exhibit 50: Global autoimmune diseases drugs market share by MOA 2015
Exhibit 51: Global autoimmune diseases drugs market segmentation by drug class
Exhibit 52: Examples of non-biologic DMARDs and biologic DMARDs for autoimmune diseases
Exhibit 53: NSAIDs used to treat autoimmune diseases
Exhibit 54: Global autoimmune diseases drugs market by drug class 2015
Exhibit 55: Global autoimmune diseases drugs market segmentation by type of molecule
Exhibit 56: Global autoimmune diseases biologics market 2015-2020 ($ billions)
Exhibit 57: Global autoimmune diseases small molecules market 2015-2020 ($ billions)
Exhibit 58: Global autoimmune diseases drugs market by type of molecules 2015
Exhibit 59: Global autoimmune diseases drugs market segmentation by ROA
Exhibit 60: Global autoimmune diseases drugs market segmentation by ROA 2015
Exhibit 61: Global autoimmune diseases drugs market segmentation by dosage form
Exhibit 62: Global autoimmune disease drugs market segmentation by dosage form 2015
Exhibit 63: Global autoimmune diseases drugs market segmentation by geography 2015
Exhibit 64: Global autoimmune diseases drugs market revenue by geography 2015-2020 ($ billions)
Exhibit 65: Autoimmune diseases drugs market in the Americas 2015-2020 ($ billions)
Exhibit 66: Autoimmune diseases drugs market in America by country 2015
Exhibit 67: Autoimmune diseases drugs market in US 2015-2020 ($ billions)
Exhibit 68: Drivers and challenges for autoimmune diseases drugs market in the US
Exhibit 69: Autoimmune diseases drugs market in EMEA 2015-2020 ($ billions)
Exhibit 70: Autoimmune diseases drugs market in APAC 2015-2020 ($ billions)
Exhibit 71: Autoimmune diseases drugs market in Japan 2015-2020 ($ billions)
Exhibit 72: Drivers and challenges for autoimmune diseases drugs market in Japan
Exhibit 73: Autoimmune diseases drugs market in China 2015-2020 ($ billions)
Exhibit 74: Global autoimmune diseases drugs market YoY revenue and growth based on geography 2015-2020 ($ billions)
Exhibit 75: Population aged 60 years and over ($ millions)
Exhibit 76: Biologics approval timeline by US FDA
Exhibit 77: Some pipeline molecules under phases of development for autoimmune diseases
Exhibit 78: Impact of drivers
Exhibit 79: Average annual treatment cost of adalimumab, etanercept, and infliximab 2014 ($ millions)
Exhibit 80: Approval and patent expiries of top selling biologics
Exhibit 81: CAM therapies for autoimmune diseases
Exhibit 82: Usage of CAM therapies among individuals in US 2014
Exhibit 83: Adverse effects associated with autoimmune disease therapies
Exhibit 84: Impact of drivers and challenges
Exhibit 85: Patient assistance programs for autoimmune diseases drugs
Exhibit 86: Revenue share of major companies for autoimmune diseases 2015
Exhibit 87: YoY Sales comparison of top drugs 2013-2015 ($ billions)
Exhibit 88: AbbVie: Product segmentation by revenue 20150
Exhibit 89: AbbVie: YoY growth rate and revenue of HUMIRA 2013-2015 ($ billions)
Exhibit 90: AbbVie: YoY growth rate and revenue of HUMIRA in US 2013-2015 ($ billions)
Exhibit 91: AbbVie: YoY growth rate and revenue of HUMIRA in ROW 2013-2015 ($ billions)
Exhibit 92: Sales of HUMIRA in major markets
Exhibit 93: AbbVie: Key takeaways
Exhibit 94: Johnson & Johnson: Segmentation of key autoimmune diseases drugs 2014
Exhibit 95: Johnson & Johnson: YoY growth rate and revenue of Remicade 2013-2014 ($ billions)
Exhibit 96: Johnson & Johnson: YoY growth rate and revenue of Remicade in US 2013-2015 ($ billions)
Exhibit 97: Johnson & Johnson: YoY growth rate and revenue of Remicade in ROW 2013-2015 ($ billions)
Exhibit 98: Johnson & Johnson: YoY growth rate and revenue of Stelara 2013-2015 ($ billions)
Exhibit 99: Johnson & Johnson: YoY growth rate and revenue of Stelara in US 2013-2015 ($ billions)
Exhibit 100: Johnson & Johnson: YoY growth rate and revenue of Stelara in ROW 2013-2015 ($ millions)
Exhibit 101: Johnson & Johnson: YoY growth rate and revenue of Simponi/Simponi Aria 2013-2015 ($ billions)
Exhibit 102: Johnson & Johnson: YoY growth rate and revenue of Simponi/Simponi Aria in US 2013-2015 ($ millions)
Exhibit 103: Johnson & Johnson: YoY growth rate and revenue of Simponi/Simponi Aria in ROW 2013-2015 ($ millions)
Exhibit 104: Johnson & Johnson: Key takeaways
Exhibit 105: Biogen: Product segmentation of key autoimmune diseases drugs by revenue 2015
Exhibit 106: Top selling autoimmune diseases drugs
Exhibit 107: Biogen: YoY growth rate and revenue of Tecfidera 2013-2015 ($ billions)
Exhibit 108: Biogen: YoY growth rate and revenue of Avonex 2013-2015 ($ billions)
Exhibit 109: Biogen: YoY growth rate and revenue of Tysabri 2013-2015 ($ billions)
Exhibit 110: Biogen: YoY revenue of Plegridy 2014-2015 ($ millions)
Exhibit 111: Biogen: YoY growth rate and revenue of Fampyra 2013-2015 ($ millions)
Exhibit 112: Biogen: Key takeaways
Exhibit 113: Amgen: YoY growth rate and revenue of Enbrel in US and Canada 2013-2015 ($ billions)
Exhibit 114: Amgen: YoY growth rate and revenue of Enbrel in US 2013-2015 ($ billions)
Exhibit 115: Amgen: YoY growth rate and revenue of Enbrel in Canada 2013-2015 ($ millions)
Exhibit 116: Amgen: Key takeaways
Exhibit 117: Pfizer: Autoimmune diseases drugs product segmentation by revenue 2014
Exhibit 118: Top selling autoimmune diseases drugs
Exhibit 119: Pfizer: YoY growth rate and revenue of Enbrel (outside US and Canada) 2013-2015 ($ billions)
Exhibit 120: Pfizer: YoY growth rate and revenue of Celebrex 2013-2015 ($ billions)
Exhibit 121: Pfizer: YoY growth rate and revenue of Xeljanz 2012-2014 ($ millions)
Exhibit 122: Pfizer: Key takeaways
Exhibit 123: Top selling autoimmune diseases drugs
Exhibit 124: F. Hoffmann-La Roche: YoY growth rate and revenue of Actemra/RoActemra 2013-2015 ($ billions)
Exhibit 125: F. Hoffmann-La Roche: Actemra/RoActemra geographic segmentation by revenue 20155
Exhibit 126: F. Hoffmann-La Roche: YoY growth rate and revenue of MabThera/Rituxan (oncology and immunology indications) 2013-2015 ($ billions)
Exhibit 127: F. Hoffmann-La Roche: YoY growth rate and revenue of MabThera/Rituxan (immunology indications only) 2013-2015 ($ billions)
Exhibit 128: F. Hoffmann-La Roche: Geographic segmentation of MabThera/Rituxan by revenue 2015
Exhibit 129: F. Hoffmann-La Roche: Key takeaways
【レポート販売概要】
■ タイトル：自己免疫疾患用薬の世界市場2016-2020■ 英文：Global Autoimmune Drugs Market 2016-2020
■ 発行日：2016年3月18日
■ 調査会社：Technavio
■ 商品コード：IRTNTR9055
■ 調査対象地域：グローバル
- オートパイロット装置の世界市場2016-2020About Autopilot System Autopilot system is a major component of an aircraft, which is used to operate the aircraft without any pilot supervision. It consists of four major components — the computer system, actuator, gyros, and global positioning service (GPS). The computer system is used to program the autopilot system and helps the pilots to interact with the GPS and the gyros, and transfers the …
- 世界の企業向けVSAT市場動向（2012-2016）TechNavio's analysts forecast the Global Enterprise Very Small Aperture Terminal (VSAT) market to grow at a CAGR of 10.27 percent over the period 2012-2016. One of the key factors contributing to this market growth is the high return on investment. The Global Enterprise VSAT market has also been witnessing the increasing adoption of routers that have both terrestrial and satellite capabilities. Ho …
- 予測遺伝子検査と消費者/ウェルネスゲノミクスの世界市場分析：用途別（がん、糖尿病のスクリーニング、パーキンソン病、循環器、整形外科･筋骨格系、ヌートリア遺伝学、皮膚･代謝遺伝学）、動向分析、2013-2025The global predictive genetic testing & consumer/wellness genomics market is anticipated to reach USD 4.6 billion by 2025, according to a new report by Grand View Research, Inc. Key drivers attributing to the market expansion include rising awareness pertaining to the use of genomic tests for the prediction of gene susceptibility for probability of disease development. Genetic data in the ecosyste …
- 流量センサの世界市場2015-2019About Flow Sensors Flow sensors are used for measuring the flow of liquids, slurries, viscous media, gases, air, steam, and bulk solid materials. The device constitutes indicator, scale, top, and tube. The sensitivity varies depending on different characteristics of the fluid, like density, pressure, temperature, and viscosity. The performance of the flow sensor is measured based on parameters, su …
- ミックスシグナルSoCの世界市場2019-2023About this market Mixed signal SoCs are increasingly being deployed in mobile phones, computers, car engines, and wearable devices due to continuous miniaturization. These mixed signal SoCs also enable the conversion of analog signals including sound, light, and heat into digital signals for processing. The integration of several components on a single IC further enables device manufacturers in de …
- 特殊肥料（高効率肥料）の世界市場：リン酸モノアンモニウム、リン酸一カリウム、硝酸カリウム、塩化カリウム、硫酸カリウム、尿素、UANSpecialty fertilizers such as slow/controlled-release fertilizers and water-soluble fertilizers are also known as enhanced efficiency fertilizers. These fertilizers release nutrients slowly or gradually into the soil at a pre-determined time and rate. Specialty fertilizers are gaining importance due to the global awareness regarding sustainable agriculture, which demands step-by-step reduction in …
- 農業経営管理ソフトウェアの世界市場予測（～2022）The farm management software market is expected to grow from USD 1.14 Billion in 2015 to USD 4.07 Billion by 2022, at a CAGR of 17.2% between 2016 and 2022. Farm management software provides agricultural technology services to growers. Its applications include crop management, financial management, farm inventory, weather forecasting, and others. Farm management software has revolutionized the way …
- マイクロチャンネル熱交換器の世界市場展望2017-2026According to Stratistics MRC, the Global Microchannel Heat Exchanger Market is accounted for $8.74 billion in 2017 and is expected to reach $29.57 billion by 2026 growing at a CAGR of 14.5% during the forecast period. Some of the key factors influencing the market growth include increasing demand for HVACR industry and energy efficiency regulations. However, the production of low-cost in emerging …
- レゾルシノール・ジメチルエーテルの世界市場Resorcinol Dimethyl Ether (CAS 151-10-0) Market Research Report 2013 presents comprehensive data on resorcinol dimethyl ether markets globally and regionally (Europe, Asia, North America etc.) The Resorcinol Dimethyl Ether (CAS 151-10-0) Market Research Report 2013 includes resorcinol dimethyl ether description, covers its application areas and related patterns. It overviews resorcinol dimethyl et …
- 超音速ビジネスジェット（SBJ）の世界市場2016-2020About Supersonic Business Jet A supersonic business jet (SBJ) is a small business private carrier, which can accommodate 10 to 12 passengers and can fly at a speed of more than Mach 1. It efficiently reduces the travel time to half, as compared to other conventional business aircraft. Currently, aviation experts such as Airbus, Lockheed Martin, Aerion, HyperMach, and Gulfstream Aerospace develop s …
- 止血剤の世界市場：トロンビン、酸化再生セルロース、併用止血剤、ゼラチン、コラーゲンThe global hemostats market is projected to reach USD 2.76 Billion by 2020 at a CAGR of 6.2% from 2015 to 2020. The Americas market contributed the largest share to the global market in 2014, wherein the U.S. dominating the Americas market. The report on global hemostats market analyzes and segments the market on the basis of product and region. It analyzes the competitive developments, such as al …
- 血糖モニタリング機器の世界市場：血糖ストリップ、血糖測定器、ランセットAbout Blood Glucose Monitoring (BGM) Diabetes is a disease that occurs when the body is unable to produce insulin, or when the glucose rises above the required levels. Insulin, a hormone produced by the pancreas, is used to process glucose, which acts as a fuel for the tissues. BGM is the process of testing the concentration of insulin or glucose in the blood. A blood glucose meter is a small elec …
- 世界のエレクトロクロミックガラス市場2015The Global Electrochromic Glass Industry 2015 Market Research Report is a professional and in-depth study on the current state of the Electrochromic Glass industry. The report provides a basic overview of the industry including definitions, classifications, applications and industry chain structure.The Electrochromic Glass market analysis is provided for the international markets including develop …
- 世界のトランスミッション液市場2015The Global Transmission Fluid Industry 2015 Market Research Report is a professional and in-depth study on the current state of the Transmission Fluid industry. The report provides a basic overview of the industry including definitions, classifications, applications and industry chain structure.The Transmission Fluid market analysis is provided for the international markets including development t …
- ステンレス鋼線材の世界市場ABSTRACTAbout Stainless Steel Wire Rod Stainless steel wire rods are manufactured by hot rolling billets on continuous rolling mills. They are wound up in coils and have a round cross-section. Stainless steel wire rods have high tensile strength and are used in various industrial applications such as reinforcing materials for tires and conveyor belts. Stainless steel wire rods are manufactured by …
